2026 Global: Bioabsorbable Stents Market -Competitive Review (2032) report
Description
The 2026 Global: Bioabsorbable Stents Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for bioabsorbable stents market by geography and historical trend. The scope of the report extends to sizing of the bioabsorbable stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical, Kyoto Medical Planning Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Meril Life Sciences, Reva Medical, LLC, and Terumo Corporation dominate the bioabsorbable stents market. These ten companies lead through innovation in polymer-based and metal-based scaffolds, capturing significant shares amid rising cardiovascular disease prevalence. Boston Scientific Corporation excels with advanced drug-eluting systems like Synergy, emphasizing bioabsorbable polymers for reduced long-term complications. Biotronik SE & Co. KG advances with Freesolve scaffolds, earning FDA Breakthrough Device Designation in March 2024 for coronary interventions, bolstering its position via clinical data on patency and resorption. Terumo Corporation and Kyoto Medical Planning Co., Ltd. focus on next-generation platforms, leveraging Asia-Pacific growth at 11.78% CAGR through localized manufacturing and regulatory alignments in China and Singapore.
Elixir Medical and Reva Medical, LLC pioneer polymer platforms like poly-L-lactic acid scaffolds, holding 64.34% market dominance in 2024 due to refined strut thickness and drug-elution kinetics. Lepu Medical Technology (Beijing) Co., Ltd. and Meril Life Sciences expand via cost-leadership in emerging markets, forming joint ventures for magnesium alloys and PLLA supplies to counter geopolitical risks. B. Braun SE invests in R&D for SLENDER IDS and DIRECT RX systems, targeting coronary artery disease with rapid-exchange designs. Arterius Limited contributes specialized biomaterials, supporting repeat treatments by fully degrading post-healing. These firms control nearly 60% of revenue, with top players like Abbott (via Esprit BTK FDA approval in April 2024) and MicroPort Scientific (Firesorb trials) intensifying competition through AI imaging and acquisitions like Kaneka’s 2023 Japan Medical Device Technology buyout.
Market leaders drive growth from USD 438-497 million in 2024-2025 to USD 786-813 million by 2030-2033 at 5.6-6.72% CAGRs, fueled by hospital adoptions and polymer innovations over metal stents. MicroPort’s Firesorb and 10 million stent milestone underscore global shipments, with overseas sales nearing 30% via Firehawk Liberty and OCT systems. Boston Scientific, Terumo, and MicroPort claimed largest shares in 2024 through geographic expansions and product launches in untapped regions like India’s public tenders. Competitive strategies include patent remixes post-cliffs and university collaborations, positioning Asia-Pacific as the fastest-growing area amid North America’s 38.59% dominance. Overall, these companies prioritize clinical reliability, restoring vessel function while minimizing thrombosis risks.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for bioabsorbable stents market by geography and historical trend. The scope of the report extends to sizing of the bioabsorbable stents market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical, Kyoto Medical Planning Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Meril Life Sciences, Reva Medical, LLC, and Terumo Corporation dominate the bioabsorbable stents market. These ten companies lead through innovation in polymer-based and metal-based scaffolds, capturing significant shares amid rising cardiovascular disease prevalence. Boston Scientific Corporation excels with advanced drug-eluting systems like Synergy, emphasizing bioabsorbable polymers for reduced long-term complications. Biotronik SE & Co. KG advances with Freesolve scaffolds, earning FDA Breakthrough Device Designation in March 2024 for coronary interventions, bolstering its position via clinical data on patency and resorption. Terumo Corporation and Kyoto Medical Planning Co., Ltd. focus on next-generation platforms, leveraging Asia-Pacific growth at 11.78% CAGR through localized manufacturing and regulatory alignments in China and Singapore.
Elixir Medical and Reva Medical, LLC pioneer polymer platforms like poly-L-lactic acid scaffolds, holding 64.34% market dominance in 2024 due to refined strut thickness and drug-elution kinetics. Lepu Medical Technology (Beijing) Co., Ltd. and Meril Life Sciences expand via cost-leadership in emerging markets, forming joint ventures for magnesium alloys and PLLA supplies to counter geopolitical risks. B. Braun SE invests in R&D for SLENDER IDS and DIRECT RX systems, targeting coronary artery disease with rapid-exchange designs. Arterius Limited contributes specialized biomaterials, supporting repeat treatments by fully degrading post-healing. These firms control nearly 60% of revenue, with top players like Abbott (via Esprit BTK FDA approval in April 2024) and MicroPort Scientific (Firesorb trials) intensifying competition through AI imaging and acquisitions like Kaneka’s 2023 Japan Medical Device Technology buyout.
Market leaders drive growth from USD 438-497 million in 2024-2025 to USD 786-813 million by 2030-2033 at 5.6-6.72% CAGRs, fueled by hospital adoptions and polymer innovations over metal stents. MicroPort’s Firesorb and 10 million stent milestone underscore global shipments, with overseas sales nearing 30% via Firehawk Liberty and OCT systems. Boston Scientific, Terumo, and MicroPort claimed largest shares in 2024 through geographic expansions and product launches in untapped regions like India’s public tenders. Competitive strategies include patent remixes post-cliffs and university collaborations, positioning Asia-Pacific as the fastest-growing area amid North America’s 38.59% dominance. Overall, these companies prioritize clinical reliability, restoring vessel function while minimizing thrombosis risks.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
